전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-1 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

umbilical cord blood CD19-BCMA CAR-T cells infusion (umbilical cord blood CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBeth ChristianPhase 2

veltuzumab (veltuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active
AntibodyLimited DatastaleBeth ChristianPhase 2

veltuzumab and milatuzumab (veltuzumab and milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, vinorelbine and trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastalePartner Therapeutics, Inc.Phase 2

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion

#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#monoclonal-antibody#NSCLCHarboringNRG1Fusion+1
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

BHP01 (α-PD-L1/4-1BB DLL3 CAR-T, α-PD-L1/4-1BB DLL3 CAR-T (BHP01))

Small Cell Lung Cancer Extensive Stage · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

103 / 103 pages

← PreviousNext →